The RE-TyPE study, sponsored by Sahlgrenska University Hospital, aims to enhance the understanding of pulmonary embolism (PE) outcomes through innovative longitudinal assessments. By focusing on intermediate-high risk patients, the study addresses a significant unmet need in risk stratification and management of PE, which remains a leading cause of morbidity and mortality. The findings could lead to improved treatment protocols and patient outcomes, potentially influencing clinical guidelines and establishing a new standard of care. The absence of a dedicated national PE registry in Sweden highlights the potential for RE-TyPE to fill a critical gap in clinical data, making it a valuable asset for stakeholders in the cardiovascular and pulmonary therapeutic areas. The study's outcomes may also attract interest from pharmaceutical companies looking to develop targeted therapies or diagnostic tools for PE management.